← Back to Search

Unknown

Cohort 1 (healthy volunteers) for Type 2 Diabetes

Phase 1
Waitlist Available
Led By Esther Yoon, MD
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1 to day 3
Awards & highlights

Summary

This trial tests a new drug, AZD0186, on healthy adults to ensure it is safe and understand how the body processes it.

Eligible Conditions
  • Type 2 Diabetes

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1 to day 3
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 to day 3 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adverse Events (AEs), and Serious Adverse Events (SAEs)
Secondary outcome measures
Area under plasma concentration-time curve from zero to infinity (AUCinf)
Area under the plasma concentration-time curve from 0 to the last quantifiable concentration (AUClast)
Maximum observed concentration (Cmax)

Trial Design

4Treatment groups
Experimental Treatment
Group I: Cohort 4 (healthy volunteers - food effect)Experimental Treatment2 Interventions
One of the Part 1 cohorts (planned for Cohort 6, can be updated pending emerging data) will continue into the food-effect part after a washout period. This part will be initiated after SRC review of all available data from preceding cohorts in this study.
Group II: Cohort 3 (healthy Chinese volunteers)Experimental Treatment2 Interventions
The planned number of Chinese cohorts is 1, but more than 1 cohort may be included if it is considered necessary to repeat a dose level or if additional dose steps are required. No sentinel dosing will be performed for the Chinese cohort.
Group III: Cohort 2 (healthy Japanese volunteers)Experimental Treatment2 Interventions
The planned number of Japanese cohorts is 1, but more than 1 cohort may be included if the SRC considers it necessary to repeat a dose level or if additional dose steps are required. No sentinel dosing will be performed for the Japanese cohort.
Group IV: Cohort 1 (healthy volunteers)Experimental Treatment2 Interventions
The planned number of cohorts is up to 6 cohorts; additional cohorts may be included if it is considered necessary to repeat a dose level or if additional dose steps are required for safety purposes. Six subjects will receive AZD0186, and two subjects will receive placebo.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Placebo
1995
Completed Phase 3
~2670

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,302 Previous Clinical Trials
288,624,568 Total Patients Enrolled
ParexelIndustry Sponsor
306 Previous Clinical Trials
101,052 Total Patients Enrolled
Esther Yoon, MDPrincipal InvestigatorPAREXEL Early Phase Clinical Unit-Los Angeles
5 Previous Clinical Trials
163 Total Patients Enrolled
~12 spots leftby Sep 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top